All In Biotech

NDA 209400 · Dexcel

Omeprazole

Omeprazole · Oral · Proton Pump Inhibitor

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 5, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

988

158 Phase 3, 48 recruiting

FAERS reports

349,830

257,870 serious, 31,667 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2026.

Use • treats frequent heartburn (occurs 2 or more days a week) • not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OMEPRAZOLE · OMEPRAZOLE 20MG · TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.

All 988 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue21,081
  • nausea21,009
  • diarrhoea20,814
  • dyspnoea17,286
  • drug ineffective16,663
  • headache15,621
  • pain14,599
  • chronic kidney disease14,128
  • vomiting14,011
  • dizziness13,943
  • off label use13,640
  • acute kidney injury12,307

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,484
20053,085
20063,080
20073,247
20084,328
20095,458
20107,438
20119,825
201212,809
201312,142
201414,808
201521,189
201623,502
201722,186
201828,715
201932,211
202025,702
202122,376
202221,235
202320,124
202419,421
202519,837
202614,619

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Omeprazole (Omeprazole)

2024 spending

$367M

Beneficiaries

7,509,766

28,883,231 claims

Per beneficiary

$49

$0.17 per unit

View as table
YearSpending
2020$396,295,521
2021$437,014,108
2022$400,120,884
2023$422,372,657
2024$366,738,344

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,390 on PubMed

Sponsor: Dexcel

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.